InspireMD (NSPR) Q2 2025 Earnings Transcript

InspireMD reported Q2 revenue of $1.8 million, up 2% year over year, while the bigger story was FDA premarket approval for CGuard Prime, enabling an immediate U.S. commercial launch. Management said early traction is underway, with procedures completed by double-digit physicians, stocking orders in place, and more than $58 million raised post-quarter to fund expansion. The company also guided C-GUARDIANS III clearance and launch to 2027, a later timeline than previously expected, but framed the shift as a realistic regulatory and enrollment adjustment.

Analysis

NSPR’s setup is less about this quarter’s revenue print and more about whether the company can convert regulatory de-risking into a durable reimbursement and account-opening flywheel. The first real inflection is not U.S. revenue itself but the quality of early adoption: stocking orders and procedure counts matter because they signal formulary conversion, which is the gating item for multi-hospital penetration. If that translation works, the company’s existing field footprint can create operating leverage quickly; if not, the launch remains a science project with a very expensive commercial layer.

The bigger second-order effect is competitive: a credible FDA-approved stent-first platform pressures incumbent carotid workflows by pulling procedure volume toward endovascular settings, especially at high-volume accounts where claims data targeting is most efficient. That should be more disruptive to slower-moving surgical and device incumbents than the headline launch suggests, because physician switching costs are lower once one or two flagship accounts validate outcomes and workflow. The TCAR delay is actually helpful in the near term because it concentrates the story on the cleaner CAS launch, reducing product complexity while the company builds reference sites.

Balance-sheet risk is materially improved by the post-quarter capital raise, but dilution is now part of the growth model, not a one-off event. The key watch item over the next 2-3 quarters is gross margin: if early U.S. adoption comes with low utilization and production variances, the launch can consume cash faster than the market expects. The market is likely underestimating the time needed for hospital approvals and procurement cycles, which means the stock can stay well ahead of fundamentals for months before either compounding into a real re-rate or fading on execution slippage.

Key Decisions for Investors

• Long NSPR only as a catalyst trade, not a fundamental core holding: buy on pullbacks after launch-related volatility with a 3-6 month horizon; upside is tied to evidence of repeat account openings, while downside is sharp if procedures fail to scale beyond pilot sites.
• Use call spreads in NSPR instead of common stock for launch optionality (3-9 months): the name has asymmetric upside if early U.S. adoption converts, but dilution and operating burn make straight equity exposure less attractive.
• Pair trade: long NSPR / short a carotid incumbent or broader med-device laggard if available in the portfolio, for a relative-value bet on launch-driven share gain rather than absolute market beta.
• If you already own NSPR, sell covered calls against 3-6 month upside until management proves sequential U.S. revenue acceleration; near-term sentiment is likely to over-discount the launch and then retrace on execution delays.
• Do not chase after any single upbeat update; wait for evidence of 2 consecutive quarters of U.S. commercial revenue and account expansion before sizing a larger long.